INTERCEPT PHARMACEUTICALS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Cash flows from operating activities:
Net income (loss)
Less: Income (loss) from operations of discontinued operations, net of tax
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Stock-based compensation
(Accretion) amortization of (discount) premium on investment debt securities
Amortization of deferred financing costs
Realized loss on investments
Write-off of fixed Asset
Depreciation
Non-cash operating lease cost
Accretion of debt discount
2023 Convertible Notes
2026 Convertible Notes
Total accretion of debt discount
Loss (gain) on early extinguishment of debt
Gain on lease termination
Loss on the disposal of fixed assets
Provision for allowance on credit losses, net of write-offs
Changes in operating assets:
Accounts receivable
Prepaid expenses and other current assets
Inventory
Security deposits
Other assets
Changes in operating liabilities:
Accounts payable, accrued expenses and other current liabilities
Operating lease liabilities
Interest payable
Deferred revenue
Long-term other liabilities

Net cash used in operating activities - continuing operations
Net cash provided by operating activities - discontinued operations
Net cash used in operating activities
Cash flows from investing activities:
Purchases of investment debt securities
Sales and maturities of investment debt securities
Purchases of equipment, leasehold improvements, and furniture and fixtures
Net cash (used in) provided by investing activities - continuing operations
Net cash provided by investing activities - discontinued operations
Net cash provided by investing activities
Cash flows from financing activities:
Payments for repurchases of convertible senior notes
Proceeds from exercise of options, net
Payments of debt issuance costs
Payments of employee withholding taxes related to stock-based awards
Payments for repurchase of common stock
Proceeds from issuance of Notes, net of debt issuance costs
Proceeds from terminations of capped call options
Net cash (used in) provided by financing activities - continuing operations
Net cash (used in) provided by financing activities
Effect of exchange rate changes
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents - beginning of period
Cash and cash equivalents - end of period

Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net (decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Less: Cash, cash equivalents and restricted cash of discontinued operations
Cash, cash equivalents and restricted cash of continuing operations

Comments